SCHEMBL1675913

SCHEMBL1675913

CCC1(F)CN(c2ccccc2)c2nc(Nc3ccc(C(=O)O)cc3OC)ncc2N(C)C1=O

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLK1 P53350 14/20 0.64
BRD4 O60885 8/20 0.52
BRDT Q58F21 5/20 0.52
MAPK7 Q13164 4/20 0.49
PLK3 Q9H4B4 4/20 0.49
DCLK1 O15075 3/20 0.49
LRRK2 Q5S007 2/20 0.49
PLK2 Q9NYY3 2/20 0.49
RAD52 P43351 1/20 0.48
PRKD3 O94806 2/20 0.48
CLK2 P49760 2/20 0.48
PTK2 Q05397 2/20 0.48
CAMK2G Q13555 2/20 0.48
CAMK2D Q13557 2/20 0.48
PRKD2 Q9BZL6 2/20 0.48
CSNK1G1 Q9HCP0 2/20 0.48
CSNK1G3 Q9Y6M4 2/20 0.48
MAP4K4 O95819 1/20 0.48
PRKCG P05129 1/20 0.48
RPS6KA3 P51812 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1675730 0.92 PLK1 (0.69) PLK1BRD4BRDTMAPK7PLK3
SCHEMBL1559373 0.91 PLK1 (0.60) PLK1BRD4BRDTMAPK7PLK3
SCHEMBL1675621 0.90 PLK1 (0.80) PLK1BRD4BRDTMAPK7PLK3
SCHEMBL4107445 0.90 PLK1 (0.54) PLK1BRD4BRDTMAPK7PLK3
SCHEMBL1675699 0.90 PLK1 (0.54) PLK1BRD4BRDTMAPK7PLK3
SCHEMBL3994195 0.88 BRD4 (0.52) PLK1BRD4BRDTMAPK7PLK3
SCHEMBL1675847 0.87 PLK1 (0.82) PLK1BRD4BRDTMAPK7PLK3
SCHEMBL1675889 0.87 PLK1 (0.62) PLK1BRD4BRDTMAPK7PLK3
SCHEMBL1675911 0.87 PLK1 (0.81) PLK1BRD4BRDTPLK3PLK2
SCHEMBL12558087 0.85 BRD4 (0.59) PLK1BRD4BRDTMAPK7PLK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2564850-B1 Polo-like kinase inhibitors TAKEDA PHARMACEUTICAL (JP) 2014-08-13 EP disclosed
EP-2564850-A1 Polo-like kinase inhibitors Takeda Pharmaceutical Company Limited (JP) 2013-03-06 EP disclosed
US-8318727-B2 Polo-like kinase inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-11-27 US disclosed
US-8026234-B2 Polo-like kinase inhibitors TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-09-27 US disclosed
US-20110201818-A1 POLO-LIKE KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-08-18 US disclosed
US-20110082111-A1 POLO-LIKE KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-04-07 US disclosed
EP-2205241-A1 POLO-LIKE KINASE INHIBITORS Takeda Pharmaceutical Company Limited (JP) 2010-07-14 EP disclosed
US-20090281092-A1 POLO-LIKE KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-12 US disclosed
WO-2009042711-A1 POLO-LIKE KINASE INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-04-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281092-A1 POLO-LIKE KINASE INHIBITORS PLK1, PLK2, POLK PLK1 1/4885BRD4 1323/4885BRDT 579/4885
US-20110201818-A1 POLO-LIKE KINASE INHIBITORS PLK1, PLK2, POLK PLK1 1/4885BRD4 1323/4885BRDT 579/4885
US-20110082111-A1 POLO-LIKE KINASE INHIBITORS PLK1, PLK2, POLK PLK1 1/4885BRD4 1323/4885BRDT 579/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.